Femasys (FEMY) versus The Competition Head-To-Head Comparison

Femasys (NASDAQ:FEMY – Get Rating) is one of 213 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Femasys to similar businesses based on the strength of its profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Femasys and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Femasys	$1.18 million	-$7.54 million	-1.74
Femasys Competitors	$1.15 billion	$84.54 million	-502.95

Femasys’ competitors have higher revenue and earnings than Femasys. Femasys is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

4.5% of Femasys shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 14.3% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Femasys and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-733.65%	-31.42%	-28.81%
Femasys Competitors	-748.46%	-65.03%	-19.49%

Analyst Recommendations

This is a breakdown of current ratings for Femasys and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	0	0	3	0	3.00
Femasys Competitors	1279	4597	7993	221	2.51

Femasys presently has a consensus target price of $11.48, suggesting a potential upside of 541.53%. As a group, “Surgical & medical instruments” companies have a potential upside of 54.74%. Given Femasys’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Femasys is more favorable than its competitors.

Femasys Company Profile (Get Rating)

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.